In his recommendations to investors, Analyst Dan Leonard says some of his top life sciences picks are those companies with the most exposure to government and academic research.
“Right now I am more predisposed to recommending stocks that have a good amount of exposure to academic and government-sponsored research in the tool space because I think that’s a good growth trend worldwide currently,” said Leonard, vice president at First Analysis Corporation. With a more favorable spending environment forecasted for 2010, such public grants and research could make up for sparse R&D budgets coming off of 2009.
“Academic and government-sponsored research support could be improving worldwide. You not only have the NIH stimulus in the U.S., but you have some science stimulus programs happening around the world in places like France and Germany,” he said. “And it looks like the Japanese science spending is actually improving a bit and showing the first signs of life in a long time.”
Other important trends Leonard emphasized to investors are molecular diagnostics, next-generation sequencing and companion diagnostics. Among these three areas he highlights companies Hologic (HOLX), Gen-Probe (GPRO), Qiagen (QGEN) and Illumina (ILMN).
SunCoke Energy, Inc. (SXC) Asset Sale Could Mean Up To 50% Upside
December 11, 2013
Commodity Stabilization Could Mean Attractive Upside for NGL Energy Partners LP (NGL)
April 06, 2015
Recommended Reading – CEO and CFO Career Consequences to Missing Quarterly Earnings Benchmarks – Academic Paper
September 24, 2008
Greater Upside for Apple Inc. (NASDAQ:AAPL)
March 28, 2016
Wade Guenther Sees Greater Upside in German Stocks: Low Cost Exposure through DAX ETF
September 18, 2017
